Moderna

Serina Therapeutics' Chief Development Officer, Randall Moreadith, presented at the 3rd Annual LNP Immunogenicity & Toxicity Summit on Serina's POZ-lipid, which showed no IgM or IgG antibody responses in animal models, contrasting with standard PEG-lipids that elicit such responses, potentially leading to safer LNP formulations.

References highlight mRNA delivery via lipid nanoparticles, mRNA vaccine progress, CRISPR-Cas9 gene editing, and nanoparticulate RNA systems, with focus on safety, efficacy, and therapeutic applications.

Global cancer vaccines market to reach USD 20.47 billion by 2032 from USD 10.61 billion in 2024, driven by R&D investments, technological advancements, and rising cancer incidence. Key players include Merck & Co., GSK plc, and others, focusing on precision medicine and mRNA-based vaccines.

2024 mirrors 2023 in biotech, with middle-market companies in survival mode. A post-pandemic hangover persists, marked by a 'haves and have-nots' dynamic favoring later-stage assets. Biopharma raised $20.8B in 2024 vs. $54.1B in 2021, with layoffs and IPO struggles. Uncertainty under the new administration impacts the industry, but M&A activity is picking up.

Tel Aviv University researchers developed a COVID-19 vaccine that can be stored at room temperature and administered as a nasal spray, breaking Pfizer and Moderna's duopoly. The nanovaccine, composed of 200-nanometer particles, trains the immune system against all common variants and doesn't require cold storage, making it ideal for developing countries.

Astellas' Vyloy, a first-in-class gastric cancer treatment, faced complex development challenges, including manufacturing setbacks and the need for a companion diagnostic from Roche. Dr. Tadaaki Taniguchi, Astellas' chief medical officer, highlights the importance of biomarker identification, diagnostic development, and physician education in precision medicine. The approval of Vyloy alongside Roche's diagnostic underscores the collaborative efforts required in oncology precision medicine. Astellas aims to expand Vyloy's use to pancreatic cancer and continues to explore new treatment modalities in oncology.

Pediatric COVID-19 vaccines under EUA could be at risk if pulled by HHS, unlike fully licensed vaccines.

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.

Colin Hill, CEO of Aitia (formerly Gene Network Sciences), discusses the evolution of AI in drug discovery, emphasizing the need to unravel the underlying circuitry of human disease. Hill highlights the importance of causal AI and digital twins in identifying novel drug targets and improving clinical trial design. He anticipates a transformative impact on biomedicine as AI-driven discoveries reach clinical stages, despite potential challenges and backlash.